gml-1 gml-1 gml-1 is a tspo (peripheral benzodiazepine receptor) ligand with anxiolytic activity. its binding affinity (ki value) to tspo is comparable with pk11195. gml-1 is selective for tspo versus the central benzodiazepine receptor (cbr, gabaa receptor). the compound gml-1 was the most active of a series of 1-arylpyrrolopyrazine-3-carboxamides, and its anxiolytic effects were examined using the open field test (oft) and the elevated plus maze (epm) test. the epm test is a general anxiety test measuring the time spent by animals in the open or the enclosed arms. when compound was administered to cd-1 mice at the dose of 1.0 mg/kg, it significantly increased the percentage of open arm entries and the time spent in the open arms. gml-1 is a potential antianxiety agent. gml-1identifiers iupac name n-benzyl-n-methyl-1-phenylpyrrolopyrazine-3-carboxamide pubchem cid122393153chemical and physical dataformulac22h19n3omolar mass341.4 g·mol−1 ny (what is this?) (verify) the tspo-mechanism of anxiolytic action of gml-1 was proved by inhibitor analysis with tspo antagonist pk11195 that blocks effect of gml-1. the involvement of neurosteroids in the mechanism of action of gml-1 was confirmed by co-administration of gml-1 with neurosteroid synthesis inhibitors. the anxiolytic effect of gml-1 in elevated plus-maze tests was completely blocked by the neurosteroidogenic-enzyme inhibitors trilostane and finasteride. the tablet dosage form of gml-1 was developed and showed pronounced anxiolytic activity after intragastric administration in rats in a wide range of doses.